Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | HPGDS | O60760 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.52 |
| ▸ | STAMBP | O95630 | 1/20 | 0.52 |
| ▸ | MMP13 | P45452 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29801122 | 1.00 | KMT2A (0.66) | KMT2AMEN1HPGDSHTTLMNA | |
| SCHEMBL29801099 | 0.88 | HPGDS (0.64) | KMT2AHPGDSHTTLMNAALDH1A1 | |
| SCHEMBL24975530 | 0.88 | HPGDS (0.64) | KMT2AHPGDSHTTLMNAALDH1A1 | |
| SCHEMBL24975354 | 0.84 | HTT (0.77) | KMT2AMEN1HPGDSHTTLMNA | |
| SCHEMBL16495652 | 0.83 | HPGDS (0.82) | HPGDSLMNAMAPTMAPK1MMP13 | |
| SCHEMBL24976313 | 0.83 | HTT (0.58) | KMT2AMEN1HPGDSHTTLMNA | |
| SCHEMBL29801317 | 0.83 | HTT (0.58) | KMT2AMEN1HPGDSHTTLMNA | |
| SCHEMBL24975342 | 0.83 | HTT (0.61) | KMT2AMEN1HPGDSHTTLMNA | |
| SCHEMBL29801153 | 0.83 | HTT (0.61) | KMT2AMEN1HPGDSHTTLMNA | |
| SCHEMBL24685295 | 0.83 | MEN1 (0.64) | KMT2AMEN1HTTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023124-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| CN-114929672-A | Cancer therapy targeting cancer stem cells | 治疗方案股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023124-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, KIT, GLI1 | KMT2A 754/4885MEN1 248/4885HPGDS 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.